With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.156492-30-7,4,7-Dibromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.
[Re(CO)5Br] (247mg, 0.60mmol) and 4,7-Br2-phen(202mg, 0.60mmol) were stirred in toluene (25mL) until thereactants were dissolved completely. After refluxing the mixture for 2h under Ar-gas atmosphere, the solvent was removedunder reduced pressure. The crude product was washed with alarge amount of n-hexane, affording the facial-isomer of[Re(CO)3(4,7-Br2-phen)Br] as a dark yellow powder (408mg,91%). The purity of the complex was determined to be morethan 95% by 1HNMR, which was thought to be pure enough toemploy in the following reaction. 1HNMR (270MHz, CDCl3):delta/ppm 8.15 (d, 2H, J = 5.6Hz, 3,8-Ar-H), 8.46 (s, 2H, 5,6-ArH), 9.20 (d, 2H, J = 5.6Hz, 2,9-Ar-H). ESI-MS m/z 710([M+Na]+)., 156492-30-7
The synthetic route of 156492-30-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Article; Kang, Yuanyuan; Ito, Akitaka; Sakuda, Eri; Kitamura, Noboru; Bulletin of the Chemical Society of Japan; vol. 90; 5; (2017); p. 574 – 585;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI